Clinical Trials
19 trialsBACON
Second Affiliated Hospital, School of Medicine, Zhejiang University
RIFOC003
Peking University People's Hospital
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.
Second Xiangya Hospital of Central South University
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
The First Affiliated Hospital with Nanjing Medical University
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Zhongnan Hospital
AL3818
Advenchen Laboratories, LLC
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
CC-ANNIE
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
CAN-RESPOND
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
t
Peking Union Medical College Hospital
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
Peking Union Medical College Hospital
AK105 Combined With Anlotinib in Patients With Cervical Cancer
The First Affiliated Hospital of Zhengzhou University
Combination Therapy for First Line Treatment of Advanced Cervical Cancer
Ruijin Hospital
ANNIE
Sun Yat-sen University
ANLOLA
Jiangsu Cancer Institute & Hospital
Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer
Sun Yat-sen University
AL3818
Advenchen Laboratories, LLC
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University